Research progress of aggressive B-cell lymphoma: reports from the 19th European Hematology Association annual congress / 白血病·淋巴瘤

ABSTRACT

Aggressive B-cell lymphoma is characterized by malignant behaviour and rapid progression.Patients are prone to drug resistance or relapse of disease.The 19th European Hematology Association (EHA)annual congress explored several aspects about aggressive B-cell lymphoma.PET-CT examination provided new tools for the indication of prognosis.The elevated dose of rituximab improved the outcome of elderly male patients.Novel drugs or methods including bortezomib,ABT-199,combined targeted therapy and CNS prophylaxis have shown encouraging results in various clinical trials which provide new hope for patients with aggressive B-cell lymphoma.